← Back to headlines
Neurocrine's Friedreich Ataxia Asset Granted FDA Orphan Status
Neurocrine Biosciences has announced that its asset for treating Friedreich ataxia has been granted orphan drug status by the FDA.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
